High materiality7/10
Jefferies Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)
Why it may matterVerify against the original reporting
Analyst reiteration suggests upside potential with a bullish setup.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst Jefferies reiterates Buy rating on NAMS with a target of $45; current price around $29.74.
- Jefferies reiterates Buy rating; target $45; price $29.74
Key facts
- 01
Target: $45
- 02
Posted price: $29.74
- 03
Analyst firm: Jefferies
- 04
Analyst: Dennis Ding
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.